Gadopiclenol (VUEWAY®) for Early Detection of Leptomeningeal Disease
This clinical trial studies how well gadopiclenol (a contrast agent) used during magnetic resonance imaging (MRI) scan works for early detection of leptomeningeal disease. A major limitation in treatment of leptomeningeal disease (LMD) is the lack of reliable diagnostic tool for detection of the disease, in particular early LMD. Clinical diagnosis of LMD is limited and challenging as patients frequently present with nonspecific symptoms or minimal symptoms in the early stages of the disease. Currently, the gold standard for diagnosis of LMD is lumbar puncture with cerebrospinal fluid (CSF) sampling. The utilization of LP for diagnosis of LMD is limited by challenges. Gadopiclenol is a gadolinium-based paramagnetic contrast agent, with potential imaging enhancing activity upon MRI. Upon administration of gadopiclenol and placement in a magnetic field, this agent produces a large magnetic moment and creates a large local magnetic field, which can enhance the relaxation rate of nearby protons. This change in proton relaxation dynamics, increases the MRI signal intensity of tissues in which this agent has accumulated; therefore, contrast and visualization of those tissues is enhanced compared to unenhanced MRI. Using gadopiclenol during MRI scan may work better for early detection of leptomeningeal disease.